Fidelity Disruptive Medicine ETF (FMED US) – Portfolio Construction Methodology

The investment framework informing the actively managed Fidelity Disruptive Medicine ETF governs a global, thematic equity portfolio that normally invests ≥80% of assets in securities of companies advancing disruptive medicine, including areas such as genomics, gene therapy, immunotherapy, robotic surgery, medical devices/equipment, rare-disease platforms, technology-enabled health-care services, and consumer wellness. Research combines fundamental issuer analysis—business model durability, competitive positioning, financial condition—with quantitative portfolio construction to assemble a risk-aware set of growth and value names across market caps and developed/emerging markets, while the strategy typically concentrates in health-care industries. Position sizing reflects conviction, liquidity, and correlation considerations; diversification is managed across subsectors and innovation modalities. Rebalancing and trims crystallize when thesis milestones miss, regulatory/clinical risk alters probability-weighted outcomes, fundamentals or valuations deteriorate, or higher-ranked opportunities emerge, while maintaining theme purity and investability.

To explore FMED in more depth, visit our ETF analytics platform for institutional-grade insights — including performance and risk metrics, correlations, sensitivities, and factor exposure: https://www.etfstrategy.com/etf/FMED_US